Overactive Bladder Drugs and Constipation: A Meta-Analysis of Randomized, Placebo-Controlled Trials
- 951 Downloads
Anticholinergic drugs are commonly prescribed for symptomatic treatment of overactive bladder (OAB). While recent meta-analyses have characterized the prevalence of dry mouth among patients utilizing OAB medications, prevalence of constipation has not been systematically reviewed.
To provide an effect measure for constipation associated with anticholinergic OAB drugs versus placebo.
A meta-analysis of trials with darifenacin, fesoterodine, oxybutynin, solifenacin, tolterodine, and trospium was conducted. All randomized, placebo-controlled studies of anticholinergic OAB drugs published in English language and identified in Medline and Cochrane databases were considered for inclusion in this meta-analysis. Those meeting predetermined design characteristics and having sufficient duration (≥2 weeks) were included. Constipation-related data from all included studies were abstracted.
One hundred two English-language, randomized, placebo-controlled trials were originally identified. Thirty-seven studies were ultimately included in the analysis, involving 19,434 total subjects (12,368 treatment + 7,066 placebo patients). The odds ratios for constipation compared with placebo were as follows: overall [odds ratio (OR) 2.18, 95% confidence interval (CI) = 1.82–2.60], tolterodine (OR 1.36, 95% CI = 1.01–1.85), darifenacin (OR 1.93, 95% CI = 1.40–2.66), fesoterodine (OR 2.07, 95% CI = 1.28–3.35), oxybutynin (OR 2.34, 95% CI = 1.31–4.16), trospium (OR 2.93, 95% CI = 2.00–4.28), and solifenacin (OR 3.02, 95% CI = 2.37–3.84).
Our results demonstrate that patients prescribed anticholinergic OAB drugs are significantly more likely to experience constipation. Differences in muscarinic receptor affinities among individual agents may possibly account for the modest variation in constipation rates observed; however, such a determination warrants additional research.
KeywordsMeta-analysis Adverse effects Constipation Cholinergic antagonists
This work was performed without financial support. The authors of this paper have no financial interests to declare.
- 7.Brubaker L, Fanning K, Goldberg EL, et al. Predictors of discontinuing overactive bladder medications. BJU Int. 2009.Google Scholar
- 8.Hay-Smith J, Herbison P, Ellis G, Morris A. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev. 2005;(3):CD005429.Google Scholar
- 12.Nabi G, Cody JD, Ellis G, Herbison P, Hay-Smith J. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2006;(4):CD003781.Google Scholar
- 19.Roxburgh C, Cook J, Dublin N. Anticholinergic drugs versus other medications for overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2007;(4):CD003190.Google Scholar
- 31.The CONSORT Group: CONSORT Statement Website [online]. URL: http://www.consort-statement.org/home; 2010 Accessed 04.03.10.
- 33.Alhasso AA, McKinlay J, Patrick K, Stewart L. Anticholinergic drugs versus non-drug active therapies for overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2006;(4):CD003193.Google Scholar
- 34.Jonas U, Hofner K, Madersbacher H, Holmdahl TH. Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. The International Study Group. World J Urol. 1997;15:144–151.CrossRefPubMedGoogle Scholar
- 38.Pfizer, Canada: product monograph—Detrol (tolterodine tablets) [online]. URL: http://www.pfizer.ca/english/our%20products/prescription%20pharmaceuticals/default.asp?s=1&id=8&doc=enmonograph; Accessed 04.03.10.
- 39.Appell RA. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology. 1997;50(6A Suppl):90–96; discussion 97–9.Google Scholar
- 42.Khullar V, Hill S, Laval KU, Schiotz HA, Jonas U, Versi E. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial. Urology. 2004;64(2):269–274; discussion 274–5.Google Scholar
- 43.Rackley R, Weiss JP, Rovner ES, Wang JT, Guan Z. Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia. Urology. 2006;67(4):731–736; discussion 736.Google Scholar
- 44.Novartis Pharmaceutical Corp. Center for Drug Evaluation and Research—application number 21-513; medical review: Enablex (darifenacin) extended release tablets [online]. URL: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-513_Enablex.cfm; Accessed 04.03.10.
- 45.Haab F, Stewart L, Dwyer P. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol. 2004;45(4):420–429; discussion 429.Google Scholar
- 49.Pfizer, Inc. Center for Drug Evaluation and Research—application number 22-030; drug approval package: Toviaz (Fesoterodine Fumarate) tablets [online]. URL: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022030s000TOC.cfm; Accessed 04.03.10.
- 54.Watson Pharma, Inc. Center for Drug Evaluation and Research—application number 21-351; package label: Oxytrol (oxybutynin transdermal system) [online]. URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/021351lbl.pdf; Accessed 04.03.10.
- 55.Watson Pharma, Inc. Center for Drug Evaluation and Research—application number 21-351; medical review: Oxytrol (oxybutynin transdermal system) [online]. URL: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-351_Oxytrol.cfm; Accessed 04.03.10.
- 57.Lackner TE, Wyman JF, McCarthy TC, Monigold M, Davey C. Randomized, placebo-controlled trial of the cognitive effect, safety, and tolerability of oral extended-release oxybutynin in cognitively impaired nursing home residents with urge urinary incontinence. J Am Geriatr Soc. 2008;56(5):862–870.CrossRefPubMedGoogle Scholar
- 58.Thuroff JW, Bunke B, Ebner A, et al. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. J Urol. 1991;145(4):813–816; discussion 816–7.Google Scholar
- 62.Indevus Pharmaceutical, Inc. Center for Drug Evaluation and Research—application number 21-595; drug approval package: Sanctura (Trospium Chloride) extended release capsules [online]. URL: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-595_Sanctura.cfm; Accessed 04.03.10.
- 64.Staskin D, Sand P, Zinner N, Dmochowski R. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial. J Urol. 2007;178(3 Pt 1):978–983; discussion 983–4.Google Scholar
- 65.Indevus Pharmaceutical, Inc. Center for Drug Evaluation and Research—application number 22-103; drug approval package: Sanctura XR (Trospium Chloride) extended release capsules [online]. URL: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022103s000TOC.cfm; Accessed 04.03.10.
- 67.Yamanouchi Pharma America, Inc. Center for Drug Evaluation and Research—application number 21-518; drug approval package: VesiCare (Solifenacin Succinate) tablets [online]. URL: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-518_VesiCare.cfm; Accessed 04.03.10.
- 71.Karram MM, Toglia MR, Serels SR, Andoh M, Fakhoury A, Forero-Schwanhaeuser S. Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial. Urology. 2009;73(1):14–18.CrossRefPubMedGoogle Scholar